Skip to main content

Brenzavvy FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 12, 2023.

FDA Approved: Yes (First approved January 20, 2023)
Brand name: Brenzavvy
Generic name: bexagliflozin
Dosage form: Tablets
Company: TheracosBio, LLC
Treatment for: Diabetes, Type 2

Brenzavvy (bexagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development timeline for Brenzavvy

Jan 23, 2023Approval FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.